QIAGEN’s Post

As a student, his journey started with a dream: "Working for a growing biotech company." What ensued exceeded his expectations and resulted in a pivotal change that defined his career. “QIAGEN was my employer of choice. I always wanted to know more about less. That led me to HID,” says Christian Starke, our senior technical sales manager for HID & Forensics. Over twenty years, Christian was the first member of the forensic team, which grew to 100 people and gained our customers' trust. His motivation for working in forensics has always been fighting crime. Twenty-eight years have passed since Christian first dreamed about his career. After years of hard work, networking, and fighting crime, he is now preparing for retirement. We are proud to have had Christian on our team and wish him all the best in his next chapter, where he will pursue his passions for music, art, and wildlife conservation.

🎉 Guess what day it is? It's August 1, which means it's RNA Day! ✅ RNA plays an important role in translating genetic information. We all know the central dogma – #DNA ➡ #RNA ➡ protein. However, some RNAs have other unique functions, like miRNAs. On this day, we're putting the spotlight on miRNA research. ✅ To celebrate, we've got some special gifts in store for you. If you want to grab one, test your knowledge of #miRNA. Learn more 👉 https://lnkd.in/esMqg7zb

We exceeded our outlook and delivered a solid performance in Q2 2024. Learn more 👉 https://lnkd.in/gUgiiuin ◾ Q2 2024: Net sales of $496 million (+0% actual rates, +1% constant exchange rates, CER); net loss per share of $0.83 but adjusted diluted EPS of $0.55. ➡ Net sales at CER of $502 million ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.55 CER ahead of $0.52 CER outlook. ➡ 28.4% adj. operating income margin up 1 percentage point from 27.4% in Q2 2023. ➡ Q2 2024 free cash flow up 56% to $129 million vs. Q2 2023. ◾ FY 2024 outlook updated after solid H1 2024 results ahead of outlook. ➡ Updated net sales outlook of at least $1.985 billion CER reflects solid core business trends and NeuMoDx decision. ➡ Adj. diluted EPS outlook increased to at least $2.16 CER.

“I hear mooing sometimes if I have my (office) window open.” Meet Ashley and Jamie Spychalla: The first two summer interns from our collaboration with One Health Microbiome Center at Penn State. They’ve taken some time off their normal work on the benefits of sourdough microbes and pathological microbiomes in grapes to perform projects with our product development teams. What surprised them the most? The familiarity of the research and how well skills they’ve learned in academia transferred to product development. Also, how large our campus and production facilities in Hilden are, the diversity of the workforce and the many different professions mingling in the cafeteria. What left the deepest impressions? The German concept of “Gastfreundschaft” (being a good host), how warm and welcoming the QIAGENers were from the first day on, and, oh yeah, the regional farm next to our offices.

It was a pleasure for our QIAGEN Manchester team to host for a visit Sir Patrick Vallance, the Minister for the Department for Science, Innovation and Technology of the United Kingdom.   During the visit, Sir Patrick toured the facility and met with our team, who provided an overview of our latest innovations and strategic initiatives – all aligned with advancing #science and improving #healthcare.   He took a deep interest in the products, especially our QIAcuity digital PCR platform and the expanding range of applications, as well as the role of companion diagnostics and their potential to make a difference in improving outcomes for patients with cancer as well as chronic and hereditary diseases.   This visit of such a high-ranking UK government official was a great opportunity to show how QIAGEN is achieving our vision of making improvements in life possible.

🤔 If you have ever asked yourself how to be more sustainable in the lab, then we have an answer for you: Reduce, Reuse, and Recycle!   ✅ Watch this video and join Nathan Susnik, PhD, one of our senior content managers, as he shows you how, with one tiny snap of the fingers, you can change so much!

The human body has trillions of microbes aiding digestion, boosting immunity, and influencing metabolism. So why not the same for plants and soil? Learn how manipulating plant microbiomes can help crop security 👉 https://lnkd.in/efbZTcBf

🎉 We are excited to share that QIAGEN LLC has been recognized as a Best Place to Work for Disability Inclusion by the Disability Equality Index, receiving a top score! ✅ The Disability Equality Index is widely acknowledged as the most comprehensive assessment tool that helps companies build a roadmap of measurable and tangible actions toward disability inclusion and equality. The Index measures a range of criteria for disability inclusion, all of which are reflected at QIAGEN LLC and throughout our global QIAGEN organization. 🤝 Many thanks to all QIAGENers, who continuously work to create an inclusive and welcoming environment for all employees, ensuring everyone has an equal opportunity to thrive and make a difference!

Whole genome sequencing of tuberculosis with no cell culture. Learn more 👉 https://lnkd.in/edtezyx7   Yes, it’s true, so we’ll say it again. The new QIAseq xHYB Mycobacterium tuberculosis Panel is designed using the seven major lineages of MTB and provides coverage of all AMR markers with no cell culture.